NASDAQ:SPRO - Spero Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.91 -0.03 (-0.25 %)
(As of 05/23/2018 11:01 AM ET)
Previous Close$12.24
Today's Range$11.90 - $12.24
52-Week Range$9.66 - $19.00
Volume302 shs
Average Volume63,394 shs
Market Capitalization$174.55 million
P/E Ratio-0.69
Dividend YieldN/A
BetaN/A

About Spero Therapeutics (NASDAQ:SPRO)

Spero Therapeutics logoSpero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPRO
CUSIPN/A
Phone857-242-1600

Debt

Debt-to-Equity RatioN/A
Current Ratio13.68
Quick Ratio13.68

Price-To-Earnings

Trailing P/E Ratio-0.69
Forward P/E Ratio-3.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.98 million
Price / Sales86.50
Cash FlowN/A
Price / CashN/A
Book Value$5.21 per share
Price / Book2.29

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees35
Outstanding Shares14,380,000

Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics (NASDAQ:SPRO) announced its quarterly earnings data on Thursday, May, 10th. The company reported ($0.74) EPS for the quarter, beating the Zacks' consensus estimate of ($1.20) by $0.46. The firm earned $1.15 million during the quarter, compared to analyst estimates of $0.20 million. View Spero Therapeutics' Earnings History.

What price target have analysts set for SPRO?

6 Wall Street analysts have issued 1 year target prices for Spero Therapeutics' shares. Their predictions range from $26.00 to $30.00. On average, they anticipate Spero Therapeutics' stock price to reach $27.75 in the next twelve months. View Analyst Ratings for Spero Therapeutics.

What are Wall Street analysts saying about Spero Therapeutics stock?

Here are some recent quotes from research analysts about Spero Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, "We met with Spero’s senior management today. In attendance were: Ankit Mahadevia, MD (CEO), Joel Sendek (CFO), Cristina Larkin (COO), and Sharon Klahre (IR). We come away from the meeting positive on the stock and reiterate our Overweight rating as well as our $27 PT ahead of what we expect to be several positive data readouts this year." (4/30/2018)
  • 2. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (2/21/2018)

Who are some of Spero Therapeutics' key competitors?

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the folowing people:
  • Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 37)
  • Dr. Thomas R. Parr Jr., Ph.D., Chief Scientific Officer (Age 64)
  • Mr. Joel D. Sendek, CFO & Treasurer (Age 51)
  • Ms. Cristina Larkin, Chief Operating Officer (Age 48)
  • Ms. Sharon Klahre, Director of Investor Relations

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

When did the company's lock-up period expire?

Spero Therapeutics' lock-up period expired on Tuesday, May 1st. Spero Therapeutics had issued 5,500,000 shares in its IPO on November 2nd. The total size of the offering was $77,000,000 based on an initial share price of $14.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.

Has Spero Therapeutics been receiving favorable news coverage?

Media coverage about SPRO stock has trended somewhat negative this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spero Therapeutics earned a daily sentiment score of -0.19 on Accern's scale. They also assigned news coverage about the company an impact score of 46.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (7.30%), JPMorgan Chase & Co. (1.78%), BlackRock Inc. (1.76%), DAFNA Capital Management LLC (0.21%) and Millennium Management LLC (0.08%). Company insiders that own Spero Therapeutics stock include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Institutional Ownership Trends for Spero Therapeutics.

Which institutional investors are buying Spero Therapeutics stock?

SPRO stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., DAFNA Capital Management LLC, BVF Inc. IL, BlackRock Inc. and Millennium Management LLC. Company insiders that have bought Spero Therapeutics stock in the last two years include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Insider Buying and Selling for Spero Therapeutics.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $11.91.

How big of a company is Spero Therapeutics?

Spero Therapeutics has a market capitalization of $174.55 million and generates $1.98 million in revenue each year. The company earns $-38,740,000.00 in net income (profit) each year or ($17.82) on an earnings per share basis. Spero Therapeutics employs 35 workers across the globe.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]


MarketBeat Community Rating for Spero Therapeutics (SPRO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spero Therapeutics (NASDAQ:SPRO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Spero Therapeutics in the last 12 months. Their average twelve-month price target is $27.75, suggesting that the stock has a possible upside of 133.00%. The high price target for SPRO is $30.00 and the low price target for SPRO is $26.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 2.832.802.80N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.75$27.6667$27.6667N/A
Price Target Upside: 133.00% upside83.83% upside129.03% upsideN/A

Spero Therapeutics (NASDAQ:SPRO) Consensus Price Target History

Price Target History for Spero Therapeutics (NASDAQ:SPRO)

Spero Therapeutics (NASDAQ:SPRO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2018OppenheimerSet Price TargetBuy$30.00MediumView Rating Details
5/11/2018HC WainwrightInitiated CoverageBuy$28.00HighView Rating Details
5/10/2018Cantor FitzgeraldSet Price TargetBuy$27.00HighView Rating Details
11/27/2017Bank of AmericaInitiated CoverageNeutralHighView Rating Details
11/27/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$26.00HighView Rating Details
11/27/2017CowenInitiated CoverageOutperformHighView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Spero Therapeutics (NASDAQ:SPRO) Earnings History and Estimates Chart

Earnings by Quarter for Spero Therapeutics (NASDAQ:SPRO)

Spero Therapeutics (NASDAQ:SPRO) Earnings Estimates

2018 EPS Consensus Estimate: ($3.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.67)($1.67)($1.67)
Q2 20181($0.67)($0.67)($0.67)
Q3 20181($0.79)($0.79)($0.79)
Q4 20181($0.64)($0.64)($0.64)

Spero Therapeutics (NASDAQ SPRO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($1.1960)($0.74)$0.20 million$1.15 millionViewN/AView Earnings Details
4/2/2018Q4 2017($1.77)($1.59)$0.40 million$0.99 millionViewN/AView Earnings Details
12/14/2017Q3 2017($2.43)($36.02)$0.20 million$0.60 millionViewN/AView Earnings Details
8/6/2013Q213$0.01$4.20 million$4.50 millionViewN/AView Earnings Details
3/7/2013Q412($0.40)$17.00 million$15.90 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Spero Therapeutics (NASDAQ:SPRO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/7/2015quarterly$0.01502.97%9/16/20159/18/201510/7/2015
5/6/2015quarterly$0.01503.49%6/17/20156/19/20157/7/2015
3/6/2015quarterly$0.01504.44%3/18/20153/20/20154/7/2015
11/5/2014quarterly$0.01503.59%12/17/201412/19/20141/6/2015
8/11/2014quarterly$0.01503.23%9/17/20149/19/201410/7/2014
5/9/2014quarterly$0.01502.38%6/18/20146/20/20147/7/2014
3/6/2014quarterly$0.01502.4%3/19/20143/21/20144/7/2014
11/8/2013quarterly$0.01502.79%12/17/201312/19/20131/6/2014
8/7/2013quarterly$0.01503.68%9/17/20139/19/201310/7/2013
5/8/2013quarterly$0.01503.9%6/12/20136/14/20137/5/2013
3/8/2013quarterly$0.01503.95%3/20/20133/22/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Spero Therapeutics (NASDAQ SPRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 26.90%
Institutional Ownership Percentage: 45.87%
Insider Trading History for Spero Therapeutics (NASDAQ:SPRO)
Insider Trading History for Spero Therapeutics (NASDAQ:SPRO)

Spero Therapeutics (NASDAQ SPRO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2017Casper BreumDirectorBuy214,285$14.00$2,999,990.00View SEC Filing  
11/6/2017Cristina LarkinCOOBuy1,500$14.00$21,000.00View SEC Filing  
11/6/2017Joel SendekCFOBuy5,000$14.00$70,000.00View SEC Filing  
11/6/2017Plc GlaxosmithklineMajor ShareholderBuy428,571$14.00$5,999,994.00View SEC Filing  
3/11/2013Allen S GreeneCEOBuy15,000$1.53$22,950.00View SEC Filing  
12/28/2012Zohar Ben-DovMajor ShareholderBuy22,693$1.19$27,004.67View SEC Filing  
12/24/2012Jack FingerhutPresidentBuy2,000$2.40$4,800.00View SEC Filing  
9/5/2012John J GormanDirectorBuy4,600$1.90$8,740.00View SEC Filing  
8/30/2012Allen S GreeneCEOBuy5,000$1.82$9,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spero Therapeutics (NASDAQ SPRO) News Headlines

Source:
DateHeadline
Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator PlatformSpero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
finance.yahoo.com - May 23 at 8:53 AM
 Brokerages Anticipate Spero Therapeutics (SPRO) Will Post Quarterly Sales of $620,000.00 Brokerages Anticipate Spero Therapeutics (SPRO) Will Post Quarterly Sales of $620,000.00
www.americanbankingnews.com - May 19 at 2:34 AM
Zacks: Analysts Expect Spero Therapeutics (SPRO) Will Post Earnings of -$0.88 Per ShareZacks: Analysts Expect Spero Therapeutics (SPRO) Will Post Earnings of -$0.88 Per Share
www.americanbankingnews.com - May 17 at 5:31 PM
Q2 2018 EPS Estimates for Spero Therapeutics (SPRO) Boosted by OppenheimerQ2 2018 EPS Estimates for Spero Therapeutics (SPRO) Boosted by Oppenheimer
www.americanbankingnews.com - May 16 at 7:32 AM
Spero Therapeutics (SPRO) Given a $30.00 Price Target at OppenheimerSpero Therapeutics (SPRO) Given a $30.00 Price Target at Oppenheimer
www.americanbankingnews.com - May 14 at 12:42 PM
Spero Therapeutics (SPRO) Given Average Rating of "Buy" by BrokeragesSpero Therapeutics (SPRO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 13 at 1:39 AM
Spero Therapeutics (SPRO) Issues Quarterly  Earnings ResultsSpero Therapeutics (SPRO) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 2:25 PM
Spero Therapeutics (SPRO) Now Covered by HC WainwrightSpero Therapeutics (SPRO) Now Covered by HC Wainwright
www.americanbankingnews.com - May 11 at 5:49 PM
Cantor Fitzgerald Analysts Give Spero Therapeutics (SPRO) a $27.00 Price TargetCantor Fitzgerald Analysts Give Spero Therapeutics (SPRO) a $27.00 Price Target
www.americanbankingnews.com - May 11 at 3:56 PM
Spero Therapeutics beats by $0.46, beats on revenueSpero Therapeutics beats by $0.46, beats on revenue
seekingalpha.com - May 11 at 9:45 AM
Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline UpdateSpero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update
finance.yahoo.com - May 10 at 5:01 PM
Spero Therapeutics (SPRO) PT Set at $30.00 by OppenheimerSpero Therapeutics (SPRO) PT Set at $30.00 by Oppenheimer
www.americanbankingnews.com - May 4 at 10:31 PM
Spero Therapeutics (SPRO) Lifted to Hold at ValuEngineSpero Therapeutics (SPRO) Lifted to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 6:06 PM
Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in MaySpero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
feeds.benzinga.com - May 1 at 9:55 AM
Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in MaySpero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
finance.yahoo.com - May 1 at 9:07 AM
Spero Therapeutics (SPRO) Buy Rating Reiterated at Cantor FitzgeraldSpero Therapeutics' (SPRO) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 30 at 4:12 PM
Wired News – CDC Publishes Dynavax’s HEPLISAV-B(R) ACIP Recommendations in Morbidity and Mortality Weekly ReportWired News – CDC Publishes Dynavax’s HEPLISAV-B(R) ACIP Recommendations in Morbidity and Mortality Weekly Report
finance.yahoo.com - April 25 at 9:05 AM
Spero Therapeutics (SPRO) Lock-Up Period Will Expire  on May 1stSpero Therapeutics' (SPRO) Lock-Up Period Will Expire on May 1st
www.americanbankingnews.com - April 24 at 1:18 AM
Spero Therapeutics Inc (SPRO) Given Consensus Recommendation of "Hold" by BrokeragesSpero Therapeutics Inc (SPRO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 1:30 AM
Eight presentations on SPR741 at ECCMID, collectively supporting its activity, safety and tolerabilityEight presentations on SPR741 at ECCMID, collectively supporting its activity, safety and tolerability
globenewswire.com - April 16 at 8:58 AM
Spero Therapeutics (SPRO) PT Set at $27.00 by Cantor FitzgeraldSpero Therapeutics (SPRO) PT Set at $27.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 12 at 10:23 AM
Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical MicrobiologySpero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
finance.yahoo.com - April 12 at 9:52 AM
Spero Therapeutics (SPRO) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowSpero Therapeutics (SPRO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:48 PM
These Alphabet-Backed Biotech Startups Went Public In 1Q18These Alphabet-Backed Biotech Startups Went Public In 1Q18
finance.yahoo.com - April 6 at 9:23 AM
Q1 2018 EPS Estimates for Spero Therapeutics Inc Increased by Oppenheimer (SPRO)Q1 2018 EPS Estimates for Spero Therapeutics Inc Increased by Oppenheimer (SPRO)
www.americanbankingnews.com - April 6 at 7:58 AM
FY2018 EPS Estimates for Spero Therapeutics Inc Reduced by Analyst (SPRO)FY2018 EPS Estimates for Spero Therapeutics Inc Reduced by Analyst (SPRO)
www.americanbankingnews.com - April 6 at 7:24 AM
Analysts Set Expectations for Spero Therapeutics Incs FY2022 Earnings (SPRO)Analysts Set Expectations for Spero Therapeutics Inc's FY2022 Earnings (SPRO)
www.americanbankingnews.com - April 5 at 8:46 AM
Oppenheimer Analysts Give Spero Therapeutics (SPRO) a $30.00 Price TargetOppenheimer Analysts Give Spero Therapeutics (SPRO) a $30.00 Price Target
www.americanbankingnews.com - April 4 at 8:04 AM
Spero Therapeutics misses by $0.24, beats on revenueSpero Therapeutics misses by $0.24, beats on revenue
seekingalpha.com - April 3 at 9:19 AM
Spero Therapeutics (SPRO) Announces  Earnings Results, Beats Expectations By $0.18 EPSSpero Therapeutics (SPRO) Announces Earnings Results, Beats Expectations By $0.18 EPS
www.americanbankingnews.com - April 3 at 7:46 AM
Spero Therapeutics (SPRO) Rating Reiterated by Cantor FitzgeraldSpero Therapeutics (SPRO) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - April 2 at 9:11 PM
Spero Therapeutics (SPRO) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowSpero Therapeutics (SPRO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:47 PM
Where Spero Therapeutics Inc’s (NASDAQ:SPRO) Earnings Growth Stands Against Its IndustryWhere Spero Therapeutics Inc’s (NASDAQ:SPRO) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 29 at 4:47 PM
Zacks: Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Quarterly Sales of $400,000.00Zacks: Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Quarterly Sales of $400,000.00
www.americanbankingnews.com - March 29 at 10:40 AM
-$1.56 EPS Expected for Spero Therapeutics Inc (SPRO) This Quarter-$1.56 EPS Expected for Spero Therapeutics Inc (SPRO) This Quarter
www.americanbankingnews.com - March 27 at 5:53 AM
Spero Therapeutics Inc (SPRO) Receives Average Rating of "Hold" from AnalystsSpero Therapeutics Inc (SPRO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 1:44 AM
Oppenheimer Reaffirms Buy Rating for Spero Therapeutics (SPRO)Oppenheimer Reaffirms Buy Rating for Spero Therapeutics (SPRO)
www.americanbankingnews.com - March 21 at 7:48 PM
 Brokerages Anticipate Spero Therapeutics Inc (SPRO) Will Post Quarterly Sales of $400,000.00 Brokerages Anticipate Spero Therapeutics Inc (SPRO) Will Post Quarterly Sales of $400,000.00
www.americanbankingnews.com - March 11 at 1:56 AM
VHCP Management II LLC Takes Position in Spero Therapeutics Inc (SPRO)VHCP Management II LLC Takes Position in Spero Therapeutics Inc (SPRO)
www.americanbankingnews.com - March 6 at 10:31 AM
AWM Investment Company Inc. Invests $4.11 Million in Spero Therapeutics Inc (SPRO) StockAWM Investment Company Inc. Invests $4.11 Million in Spero Therapeutics Inc (SPRO) Stock
www.americanbankingnews.com - March 6 at 4:45 AM
Spero Therapeutics to Present at March Investor ConferencesSpero Therapeutics to Present at March Investor Conferences
finance.yahoo.com - March 1 at 8:53 AM
Spero Therapeutics Inc (SPRO) Receives Average Rating of "Hold" from BrokeragesSpero Therapeutics Inc (SPRO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 1:52 AM
$400,000.00 in Sales Expected for Spero Therapeutics Inc (SPRO) This Quarter$400,000.00 in Sales Expected for Spero Therapeutics Inc (SPRO) This Quarter
www.americanbankingnews.com - February 23 at 1:28 PM
Spero Therapeutics (SPRO) Upgraded by Zacks Investment Research to HoldSpero Therapeutics (SPRO) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 21 at 1:42 PM
 Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Earnings of -$1.56 Per Share Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Earnings of -$1.56 Per Share
www.americanbankingnews.com - February 21 at 10:31 AM
Head-To-Head Survey: Aptevo Therapeutics (APVO) versus Spero Therapeutics (SPRO)Head-To-Head Survey: Aptevo Therapeutics (APVO) versus Spero Therapeutics (SPRO)
www.americanbankingnews.com - February 21 at 1:30 AM
Spero Therapeutics (SPRO) Stock Rating Lowered by Zacks Investment ResearchSpero Therapeutics (SPRO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 14 at 12:32 PM
Spero Therapeutics Inc (SPRO) Forecasted to Post FY2018 Earnings of ($3.69) Per ShareSpero Therapeutics Inc (SPRO) Forecasted to Post FY2018 Earnings of ($3.69) Per Share
www.americanbankingnews.com - February 14 at 10:46 AM
Spero Therapeutics (SPRO) Earns Overweight Rating from Analysts at Cantor FitzgeraldSpero Therapeutics (SPRO) Earns Overweight Rating from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - February 8 at 4:22 PM
Zacks: Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Post Quarterly Sales of $400,000.00Zacks: Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Post Quarterly Sales of $400,000.00
www.americanbankingnews.com - February 6 at 10:40 AM

SEC Filings

Spero Therapeutics (NASDAQ:SPRO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Spero Therapeutics (NASDAQ:SPRO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spero Therapeutics (NASDAQ SPRO) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.